Spruce Biosciences, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Spruce Biosciences, Inc. (SPRB) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $47.43 million as of 2022-06-30, per its 10-Q filed 2022-08-10.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2022-08-10
- 2022-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $47.43M.
- 2022-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $23.56M.
- 2021-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $42.96M.
- 2021-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $58.58M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2022-06-30 | $47.43M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $23.56M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $42.96M 10-Q · filed 2022-08-10 |
| 2021-09-30 | $58.58M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $78.49M 10-Q · filed 2022-08-10 |
| 2021-03-31 | $148.84M 10-Q · filed 2022-05-11 |
| 2020-12-31 | $157.37M 10-Q · filed 2022-08-10 |
| 2020-09-30 | $72.37M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $36.82M 10-Q · filed 2021-08-10 |
| 2020-03-31 | $41.62M 10-Q · filed 2021-05-12 |
| 2019-12-31 | $3.92M 10-K · filed 2022-03-14 |
| 2019-09-30 | $4.83M 10-Q · filed 2020-11-18 |
| 2018-12-31 | $4.11M 10-K · filed 2021-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |